ArticleOncology reports2026
Sphingosine‑1‑phosphate receptor 1 enhances olfactory receptor 51E1‑mediated inhibition of proliferation via Src/JNK signaling in prostate cancer cells.
Article in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Olfactory receptors (ORs) are ectopically expressed in multiple cancers and can regulate tumor cell behavior, yet their clinical relevance and regulatory mechanisms remain poorly defined. OR51E1 is highly expressed in prostate cancer (PC) and suppresses tumor cell proliferation upon activation, but its expression alone does not correlate with patient prognosis, suggesting additional regulatory factors. Using transcriptomic analyses of The Cancer Genome Atlas and Genotype‑Tissue Expression datasets, functional screening of G‑protein‑coupled receptors, and mechanistic studies in PC cells, sphingosine‑1‑phosphate receptor 1 (S1PR1) was identified as a key modulator of OR51E1 function. Activation of OR51E1 by nonanoic acid (NA) or butyric acid reduced PC cell survival in an OR51E1‑dependent manner, and this effect was abolished in OR51E1 knockout cells. S1PR1 enhanced OR51E1‑mediated signaling by increasing its surface expression and amplifying downstream apoptotic responses. Although OR51E1 activation induced cAMP signaling, NA‑induced cytotoxicity was independent of the canonical Gs/olf‑cAMP pathway and instead required Src and JNK activation, which was further potentiated by S1PR1. Clinically, co‑expression of OR51E1 and S1PR1 was significantly associated with improved progression‑free interval in patients with prostate adenocarcinoma, particularly in stage II disease, whereas OR51E1 expression alone showed no prognostic value. Collectively, these findings define a previously unrecognized OR51E1‑S1PR1 signaling axis that suppresses PC cell survival through Src/JNK‑dependent mechanisms and highlight GPCR‑mediated regulation of ectopic olfactory receptors as a determinant of tumor behavior and patient outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.